Given that Env IgG3 correlated with decreased risk of HIV-1 infection in the one partially efficacious HIV-1 vaccine trial to date (RV144), determining the underlying antiviral mechanisms is critical for improving HIV-1 prevention strategies. The gene discussed is ERVW-1; the disease is HIV-1 infection.